Management of nonalcoholic steatohepatitis: an analytic review.
Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver, which, although usually relatively mild, may in some cause fibrosis, cirrhosis, and premature death resulting from liver failure. Its prevalence is increasing, and it is probably underestimated as a cause for cirrhosis. The need for an effective treatment is clear and urgent. Although several small, pilot, and randomized studies have been reported, large-scale studies are yet to be performed in patients with NASH. The aim of therapy is to intervene early in patients at risk of progression of liver disease. In this review, we summarize the extant literature on the management of NASH and discuss the potential future therapies and prophylactic recommendations in patients with NASH.
Department of Medicine, The Liver-Biliary-Pancreatic Center of the University of Massachusetts Medical School, Worchester, USA.
Sanjay
S
Agrawal
Herbert L
HL
Bonkovsky
D003920:Diabetes Mellitus / Q000453:epidemiology; D005234:Fatty Liver / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D006505:Hepatitis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D006946:Hyperinsulinism / Q000453:epidemiology; D007501:Iron / Q000627:therapeutic use; D020738:Leptin / Q000502:physiology; D016031:Liver Transplantation; D012307:Risk Factors; D012838:Silymarin / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D020738:Leptin; D012838:Silymarin; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D014810:Vitamin E; D014580:Ursodeoxycholic Acid; D007501:Iron